Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.

Key facts

Study ID

NCT01511783

Run by

Eisai Inc.

People needed

50

Starts

2011-12-01

Expected to finish

2012-11-01

Last updated by the study team

2015-11-03

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: accepted.

Where it is running

• Compass Research Phase 1, LLC — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.